Cover Image
市場調查報告書

可溶性鳥甘酸環化酶:開發中產品分析

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365802
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
可溶性鳥甘酸環化酶:開發中產品分析 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 82 Pages
簡介

本報告提供以可溶性鳥甘酸環化酶為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

可溶性鳥甘酸環化酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Ironwood Pharmaceuticals, Inc.
  • Mallinckrodt Plc
  • NicOx S.A.
  • SynZyme Technologies, LLC

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0985TDB

Summary:

According to the recently published report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017'; Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

The report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017' outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Gastrointestinal, Immunology, Oncology, Respiratory, Central Nervous System, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease and Toxicology which include indications Ocular Hypertension, Glaucoma, Cystic Fibrosis, Resistant Hypertension, Alzheimer's Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Heart Failure, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Nephropathy, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Open-Angle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Hypertension, Sickle Cell Disease, Stroke, Systemic Sclerosis (Scleroderma), Tinea pedis (Athlete Foot), Vascular Dementias and Wounds.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
    • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Ironwood Pharmaceuticals Inc
    • NicOx SA
    • SynZyme Technologies LLC
    • Topadur Pharma AG
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
    • A-8R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1101042 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1237592 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1636183 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-703704 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyurea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IW-1701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IW-1973 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IW-6463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IWP-953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naproxcinod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-1653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-429 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-470 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-667 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitric oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Q-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • riociguat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate sGC for Osteoporosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Soluble Guanylate Cyclase for Hypertension and Parenchymal Hemorrhage - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate sGC for Liver Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOPN-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vacno - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vericiguat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 29, 2017: Bayer Now Enrolling Patients into a Global Pulmonary Arterial Hypertension Study
      • Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis
      • May 19, 2017: Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2017 International Conference
      • May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017
      • May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017
      • Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017
      • Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
      • Jan 26, 2017: Bayer and Merck to Present Riociguat Data in Rare Pulmonary Diseases at the Annual World Congress of the Pulmonary Vascular Research Institute
      • Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering
      • Oct 18, 2016: Bayer to Present Data in Pulmonary Arterial Hypertension at the 2016 Annual Meeting of the American College of Chest Physicians
      • Sep 28, 2016: Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure
      • Sep 16, 2016: Withdrawal of the marketing authorisation application for Adempas (riociguat)
      • Jun 24, 2016: Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia
      • May 13, 2016: Bayer to Present Pulmonary Hypertension Data at American Thoracic Society 2016 International Conference
      • May 12, 2016: Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Bayer AG, H2 2017
  • Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
  • Pipeline by NicOx SA, H2 2017
  • Pipeline by SynZyme Technologies LLC, H2 2017
  • Pipeline by Topadur Pharma AG, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Dormant Products, H2 2017 (Contd..3), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top